Another New Approach to Cytology
Executive Summary
The founder and former CEO of AccuMed International Inc., Peter Gombrich, has started a new company based on licensing and acquisitions in the fields of cytology and urology. He is using an innovative financing strategy that merges the privately held InPath LLC into Bell National Corp., a publically traded shell company. This allows Inpath to obtain cash and offer investors an exit, despite the coolness of public markets to small cap stocks.
You may also be interested in...
Ampersand Medical's Financing Twist
If Ampersand Medical Corp. started with an unusual financing strategy, its current efforts to get listed on a major stock exchange are also a bit innovative and circuitous. The fact that it has managed to survive and progress in a tough era for diagnostics, even though it is a late entrant into the crowded field of cervical cancer screening, is a testament to the value of this approach. Its founder, Peter Gombrich, has started several device and diagnostic companies which have acquired each other or licensed from one another, including AccuMed International and InPath. Now, Ampersand wants to buy AccuMed to gain access to short-term revenues, patents, and technologies related to early-stage cancer detection.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.